e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension
Lewis J. Rubin
Source:
Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017
Journal Issue:
September
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lewis J. Rubin. Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension. Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension
Source: Eur Respir J 2009; 34: 1100-1110
Year: 2009
Dysregulated bone morphogenetic protein signaling in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
The adverse effect of estrogen on bone morphogenetic protein receptor (BMPR) signal pathway in pulmonary arterial endothelial cells (PAEC)
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Bone morphogenetic protein receptor-II as a regulator of pulmonary artery endothelial cell permeability: Relevance to the initiation and progression of heritable pulmonary arterial hypertension
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
The microRNA cluster 17/92 regulates the expression of the bone morphogenetic protein receptor type II involved in the pathogenesis of pulmonary hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension
Year: 2009
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Pathobiology of pulmonary arterial hypertension and right ventricular failure
Source: Eur Respir J 2012; 40: 1555-1565
Year: 2012
Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
Source: Eur Respir J 2002; 20: 518-523
Year: 2002
Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Targeting BMPR-II in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches
Year: 2016
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
Oral presentation: The bone morphogenetic protein antagonist Gremlin in pulmonary hypertension
Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
Year: 2009
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease
Source: Eur Respir J 2004; 24: 371-374
Year: 2004
Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females
Source: Eur Respir J 2009; 34: 1093-1099
Year: 2009
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept